Analysts expect Dova Pharmaceuticals Inc (NASDAQ:DOVA) to post earnings of ($0.79) per share for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Dova Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.87) and the highest is ($0.75). Dova Pharmaceuticals reported earnings of ($0.36) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 119.4%. The business is scheduled to announce its next quarterly earnings results on Thursday, February 21st.
According to Zacks, analysts expect that Dova Pharmaceuticals will report full-year earnings of ($2.70) per share for the current financial year, with EPS estimates ranging from ($2.78) to ($2.65). For the next financial year, analysts expect that the firm will post earnings of ($2.50) per share, with EPS estimates ranging from ($2.90) to ($1.71). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Dova Pharmaceuticals.
Dova Pharmaceuticals (NASDAQ:DOVA) last posted its quarterly earnings results on Thursday, November 8th. The company reported ($0.69) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.12. The business had revenue of $2.93 million during the quarter, compared to analysts’ expectations of $2.66 million.
A number of research firms recently weighed in on DOVA. Zacks Investment Research downgraded Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 30th. BidaskClub upgraded Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, December 13th. HC Wainwright initiated coverage on Dova Pharmaceuticals in a research note on Thursday, December 20th. They issued a “buy” rating and a $18.00 price target on the stock. JPMorgan Chase & Co. downgraded Dova Pharmaceuticals from an “overweight” rating to an “underweight” rating and decreased their target price for the stock from $34.00 to $20.00 in a research report on Wednesday, January 23rd. Finally, LADENBURG THALM/SH SH boosted their target price on Dova Pharmaceuticals to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 18th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. Dova Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $29.50.
In other news, CEO David Zaccardelli bought 10,000 shares of the firm’s stock in a transaction on Thursday, December 20th. The shares were bought at an average cost of $6.07 per share, for a total transaction of $60,700.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Paul B. Manning bought 266,631 shares of the firm’s stock in a transaction on Thursday, December 20th. The shares were purchased at an average price of $6.17 per share, for a total transaction of $1,645,113.27. The disclosure for this purchase can be found here. 55.50% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the company. PNC Financial Services Group Inc. lifted its position in shares of Dova Pharmaceuticals by 14,705.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,034 shares of the company’s stock valued at $38,000 after acquiring an additional 5,000 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Dova Pharmaceuticals by 46.1% in the fourth quarter. Rhumbline Advisers now owns 15,343 shares of the company’s stock valued at $116,000 after acquiring an additional 4,843 shares in the last quarter. Stonepine Capital Management LLC purchased a new stake in shares of Dova Pharmaceuticals in the third quarter valued at $145,000. Tower Research Capital LLC TRC purchased a new stake in shares of Dova Pharmaceuticals in the third quarter valued at $158,000. Finally, Bank of America Corp DE lifted its position in shares of Dova Pharmaceuticals by 81.3% in the second quarter. Bank of America Corp DE now owns 5,305 shares of the company’s stock valued at $159,000 after acquiring an additional 2,379 shares in the last quarter. Institutional investors and hedge funds own 37.14% of the company’s stock.
Shares of Dova Pharmaceuticals stock traded up $0.12 during trading on Friday, reaching $7.60. The company’s stock had a trading volume of 138,988 shares, compared to its average volume of 169,031. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.50 and a quick ratio of 7.40. Dova Pharmaceuticals has a 12-month low of $5.62 and a 12-month high of $37.00. The company has a market cap of $210.97 million, a PE ratio of -5.43 and a beta of 2.03.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Further Reading: How does inflation affect different investments?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.